Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.

COVID-19 treatments in care homes
Load More

Similar stories

NHS baby check may miss dislocated hips in new-born babies

A new study has identified that NHS infant checks can miss serious hip abnormalities in new-born babies. Left undetected, these can require complex surgery, and lead to early arthritis. In the UK around 500 infants undergo surgery for dislocated hips which could have been avoidable.